此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery (TRACE)

2026年7月6日 更新者:Centre Hospitalier Universitaire de Nīmes

Evaluation of the Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery - A Single-Center, Randomized, Controlled Proof-of-Concept Study.

Acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year. Effective analgesic therapy in the first postoperative week is a key factor in reducing early postoperative morbidity and mortality. Poorly controlled APOP is a major risk factor for chronic postoperative pain. In France today, more and more patients undergo surgical procedures as outpatients. The challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either after outpatient surgery or after a prompt return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, postoperative pain management requires new strategies and/or organizational approaches to ensure high-quality pain management from the very start. The principle of analgesia for acute postoperative pain recommends: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy if maintenance therapy is insufficient, based on pain titration, using mild or strong oral opioids. Postoperative pain is the primary focus of postoperative care but the goal is also to improve postoperative recovery and enhance the patient's overall care. To date, there are no medical telemonitoring devices to support the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, enabling systematic postoperative screening for early and late warning signs of the risk of chronic pain. The Thess Monitoring device, which implements the ANTALGEEK® protocol, (TMA) was developed to optimize the efficiency of outpatient management of acute postoperative pain. It improves patients' adherence to maintenance treatment with adaptive, personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing). The aim is to ensure optimal pain resolution and improve early and late postoperative recovery during the first postoperative week. The TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain. By measuring pain scores daily during the first postoperative week, it identifies patients with a suboptimal pain trajectory who are at high risk of developing persistent pain beyond the third month. It also assesses warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway via the TMA system should make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.

研究概览

详细说明

The problem of acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year and potentially leading to numerous complications when inadequately managed. In the postoperative period, the implementation of effective analgesic therapy is a key factor in reducing early postoperative morbidity and mortality. Furthermore, poorly controlled PPS is one of the major risk factors for the development of chronic postoperative pain (CPOP). Optimizing analgesic medication to prevent an abnormal pain trajectory during the first postoperative week is a key strategy for preventing chronic postoperative pain.

Today, within the French healthcare system, an increasing number of patients undergo surgical procedures performed on an outpatient basis. The big challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either following outpatient surgery or after an early return home as part of an Enhanced Recovery After Surgery (ERAS) protocol.

In outpatient surgery, improving postoperative pain management requires the implementation of new strategies and/or organizational approaches to ensure a high-quality pain management pathway from the very beginning.

The principle of analgesia for acute postoperative pain recommends a combination of: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy-if maintenance therapy is insufficient-based on the principle of pain titration, using oral opioids (mild or strong). While postoperative pain remains the primary focus of postoperative care, the goal is also to improve postoperative recovery more broadly and thereby enhance the patient's overall care.

The assessment of postoperative recovery in outpatient surgery patients using a medical telemonitoring device is associated with a reduction in discomfort caused by various postoperative symptoms, including postoperative pain. However, to date, there is no medical telemonitoring device that both supports the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, and enables systematic postoperative screening for early and late warning signs of the risk of chronic pain.

To this end, the Thess Monitoring medical telemonitoring device (which implements the ANTALGEEK® protocol) (TMA) was developed. It is a tool for continuous therapeutic support and postoperative telemonitoring designed to optimize the efficiency of outpatient management of acute postoperative pain in patients by improving adherence to maintenance therapy, adaptive and personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing), with the goal of ensuring optimal pain resolution and improved early and late postoperative recovery during the first postoperative week (Baseline-Day 7). To achieve this, the TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain: identify, through daily measurement of pain scores during the first postoperative week, patients with a suboptimal pain trajectory who are at high risk of developing persistent postoperative pain beyond the third month; assess warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3).

Improving the patient care pathway through the TMA system should thus make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.

In this initial proof-of-concept study, the investigators aim to evaluate the performance and safety of the TMA medical device in the outpatient management of acute pain during the first postoperative week, as well as its impact on postoperative recovery and on reducing the risk of pain becoming chronic by the third postoperative month.

研究类型

介入性

注册 (估计的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Gard
      • Nîmes、Gard、法国、30029
        • 招聘中
        • Nîmes University Hospital
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patients eligible for outpatient surgery.
  • Patients undergoing surgery likely to result in moderate to severe pain.
  • Patients available for a 3-month follow-up.
  • Patients who have provided their free and informed consent.
  • Patients who have signed the consent form.
  • Patients enrolled in or covered by a health insurance plan.

Exclusion Criteria:

  • Patients participating in an interventional RIPH study involving a drug or classified as Category 1.
  • Patients in an exclusion period determined by another study.
  • Patients under judicial protection, guardianship, or conservatorship.
  • Patients unable to express consent.
  • Patient for whom it is impossible to provide informed information.
  • Pregnant, laboring, or breastfeeding patients.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Postoperative pain management : standard care
Patients receiving standard postoperative analgesic care
实验性的:Postoperative pain management using the Thess telemonitoring device
Patients being monitored with the Thess Monitoring medical telemonitoring device in conjunction with the ANTALGEEK® protocol
The Thess monitoring medical device (Thess Corp., Montpellier) uses the remote ANTALGEEK® telemonitoring protocol to manage pain in outpatients who have had surgery causing moderate-to-severe pain. It digitalizes and optimizes acute postoperative pain management at home by improving adherence to maintenance therapy, with adaptive, tailored control of analgesia through better use of opioid rescue therapy to reduce the adverse effects of opioid misuse and ensures optimal pain resolution and postoperative recovery during the first week. The ANTALGEEK decision-making algorithm and a medical telemonitoring protocol help patients follow their pain medication regimen, monitoring them in postoperative Week 1, based on the preoperative prescription, data on the patient's adherence to treatment, its efficacy and tolerability.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Performance of the TMA® medical device (TMA group) according to the QoR-15 questionnaire score in the experimental group
大体时间:Day 2
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 2
Performance of the TMA® medical device (TMA group) according to the QoR-15 questionnaire score in the standard care (control) group.
大体时间:Day 2
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 2

次要结果测量

结果测量
措施说明
大体时间
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group
大体时间:Day 1, before the intervention
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 1, before the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group
大体时间:Day 1, after the intervention
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 1, after the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group
大体时间:Day 7
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 7
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group
大体时间:Day 1, before the intervention
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 1, before the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group
大体时间:Day 1, after the intervention
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 1, after the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group
大体时间:Day 7
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score > 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Day 7
Pain progression in the experimental group
大体时间:Day 1
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 1
Pain progression in the experimental group
大体时间:Day 2
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 2
Pain progression in the experimental group
大体时间:Day 3
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 3
Pain progression in the experimental group
大体时间:Day 4
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 4
Pain progression in the experimental group
大体时间:Day 5
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 5
Pain progression in the experimental group
大体时间:Day 6
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 6
Pain progression in the experimental group
大体时间:Day 7
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 7
Pain progression in the experimental group
大体时间:Month 1
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Month 1
Pain progression in the experimental group
大体时间:Month 2
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Month 2
Pain progression in the experimental group
大体时间:Month 3
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Month 3
Pain progression in the in the standard care (control) group
大体时间:Day 1
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 1
Pain progression in the in the standard care (control) group
大体时间:Day 2
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 2
Pain progression in the in the standard care (control) group
大体时间:Day 3
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 3
Pain progression in the in the standard care (control) group
大体时间:Day 4
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 4
Pain progression in the in the standard care (control) group
大体时间:Day 5
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 5
Pain progression in the in the standard care (control) group
大体时间:Day 6
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 6
Pain progression in the in the standard care (control) group
大体时间:Day 7
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Day 7
Pain progression in the in the standard care (control) group
大体时间:Month 1
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Month 1
Pain progression in the in the standard care (control) group
大体时间:Month 2
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Month 2
Pain progression in the in the standard care (control) group
大体时间:Month 3
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Month 3
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 1
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 1
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 1
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 1
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 2
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 2
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 2
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 2
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 3
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 3
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 3
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 3
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 4
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 4
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 4
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 4
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 5
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 5
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 5
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 5
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 6
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 6
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 6
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 6
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Day 7
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 7
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Day 7
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Day 7
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 1
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Day 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 1
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Day 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 2
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Day 2
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 2
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical monitoring form
Day 2
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 3
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Day 3
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 3
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Day 3
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 4

Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up.

Data collection via the Tess Monitoring Application

Day 4
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 4
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Day 4
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 5

Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up.

Data collection via the Tess Monitoring Application

Day 5
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 5
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Day 5
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 6
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Day 6
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 6
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Day 6
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Day 7
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Day 7
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Day 7
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical monitoring form
Day 7
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Month 1
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application and a phone call to the patient
Month 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Month 1
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form and a phone call to the patient
Month 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
大体时间:Month 3
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application and a phone call to the patient
Month 3
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
大体时间:Month 3
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form and a phone call to the patient
Month 3
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
大体时间:Day 1
Data collection via the Tess Monitoring Application
Day 1
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
大体时间:Day 1
Data collection on the electronic clinical registration form
Day 1
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
大体时间:Day 2
Data collection via the Tess Monitoring Application
Day 2
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
大体时间:Day 2
Data collection on the electronic clinical registration form
Day 2
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
大体时间:Day 3
Data collection via the Tess Monitoring Application
Day 3
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
大体时间:Day 3
Data collection on the electronic clinical registration form
Day 3
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
大体时间:Day 4
Data collection via the Tess Monitoring Application
Day 4
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
大体时间:Day 4
Data collection on the electronic clinical registration form
Day 4
Prescription issued outside of those prescribed upon hospital discharge in the experimental group
大体时间:Month 3
Quantitative
Month 3
Prescription issued outside of those prescribed upon hospital discharge in the standard care(control) group
大体时间:Month 3
Quantitative
Month 3
Number of days of sick leave prescribed in the experimental group
大体时间:Month 3
Quantitative
Month 3
Number of days of sick leave prescribed in the standard care (control) group
大体时间:Month 3
Quantitative
Month 3
Satisfaction questionnaire administered to the patient in the experimental group
大体时间:Day 3
Qualitative
Day 3
Satisfaction questionnaire administered to the patient in the standard care (control) group
大体时间:Day 3
Qualitative
Day 3
Satisfaction questionnaire administered to the anesthesiologist in the experimental group
大体时间:End of the inclusion period
Qualitative
End of the inclusion period
Satisfaction questionnaire administered to the anesthesiologist in the standard care (control) group
大体时间:End of the inclusion period
Qualitative
End of the inclusion period
System Usability Scale score during the follow-up call to patients in the experimental group
大体时间:Day 30
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
Day 30
System Usability Scale score from health providers to the experimental group
大体时间:End of the inclusion period
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
End of the inclusion period
System Usability Scale score during the follow-up call to patients in the standard care (control) group
大体时间:Day 30
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
Day 30
System Usability Scale score from health providers to the standard care (control) group
大体时间:End of the inclusion period
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
End of the inclusion period
DN2 questionnaire score in the experimental group
大体时间:Post-operative Month 1
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Post-operative Month 1
DN2 questionnaire score in the experimental group
大体时间:Post-operative Month 2
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Post-operative Month 2
DN2 questionnaire score in the experimental group
大体时间:Post-operative Month 3
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Post-operative Month 3
DN2 questionnaire score in the standard care (control) group
大体时间:Post-operative Month 1
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Post-operative Month 1
DN2 questionnaire score in the standard care (control) group
大体时间:Post-operative Month 2
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Post-operative Month 2
DN2 questionnaire score in the standard care (control) group
大体时间:Post-operative Month 3
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Post-operative Month 3
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Baseline
Patient's declaration in the Thess Monitoring Application
Baseline
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Baseline
Phone call from the patient
Baseline
rate of adherence to the standard pain management regimen (non-opioid analgesics) in the in the standard care (control) group
大体时间:Day 1
Phone call from the patient
Day 1
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Day 2
Patient's declaration in the Thess Monitoring Application
Day 2
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Day 2
Phone call from the patient
Day 2
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Day 3
Patient's declaration in the Thess Monitoring Application
Day 3
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Day 3
Phone call from the patient
Day 3
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Day 4
Patient's declaration in the Thess Monitoring Application
Day 4
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Day 4
Phone call from the patient
Day 4
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Day 5
Patient's declaration in the Thess Monitoring Application
Day 5
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Day 5
Phone call from the patient
Day 5
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Day 6
Patient's declaration in the Thess Monitoring Application
Day 6
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Day 6
Phone call from the patient
Day 6
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
大体时间:Day 7
Patient's declaration in the Thess Monitoring Application
Day 7
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
大体时间:Day 7
Phone call from the patient
Day 7
Incidence of adverse effects associated with opioid use in the experimental group
大体时间:Baseline
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Baseline
Incidence of adverse effects associated with opioid use in the standard care (control) group
大体时间:Baseline
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Baseline
Adverse Events [Safety and Tolerability] in the experimental group
大体时间:Day 7
Qualitative assessment. Any adverse events of any cause related to treatment will be recorded in the electronic clinical registration form following a phone call to the patient.
Day 7
Adverse Events [Safety and Tolerability]in the standard care (control) group
大体时间:Day 7
Qualitative assessment. Any adverse events of any cause related to treatment will be recorded in the electronic clinical registration form following a phone call to the patient.
Day 7
Rate of incidents, malfunctions, and organization deviations that occurred during implementation in the experimental group
大体时间:Month 3
Qualitative
Month 3
Time spent connected to the Thess Monitoring device per patient in the experimental group
大体时间:Month 3
Quantitative, in minutes
Month 3

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月1日

初级完成 (估计的)

2026年8月1日

研究完成 (估计的)

2026年12月31日

研究注册日期

首次提交

2026年6月26日

首先提交符合 QC 标准的

2026年6月26日

首次发布 (实际的)

2026年7月2日

研究记录更新

最后更新发布 (实际的)

2026年7月8日

上次提交的符合 QC 标准的更新

2026年7月6日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅